Investigational drug · Phase 3
SH-1028
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Non-small Cell Lung Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 12, 2023 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
8
Any phase or sponsor naming "SH-1028"
First trial start
2023
May 11, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SH-1028", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-small Cell Lung Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "SH-1028" as an intervention, largest first.
- A Study to Evaluate the Safety and Efficacy of SH-1028 in Locally Advanced or Metastatic NSCLCStatus unknown
Nanjing Sanhome Pharmaceutical, Co., Ltd.Industry
NCT03823807 · 300 participants (planned) · Start Mar 2019 · Primary completion Dec 2020
Drug: SH-1028 · For: Non-Small Cell Lung Cancer
- SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR MutationsPivotal-lookingRecruiting
Nanjing Sanhome Pharmaceutical, Co., Ltd.Industry
NCT06080776 · 242 participants (planned) · Start May 11, 2023 · Primary completion Feb 1, 2028
Drug: SH-1028 tablets; Placebo SH-1028 tablets · For: Non-small Cell Lung Cancer
Sites: Shanghai, China
- A Study of SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung CancerPivotal-lookingStatus unknown
Nanjing Sanhome Pharmaceutical, Co., Ltd.Industry
NCT04239833 · 240 participants (planned) · Start Jan 31, 2020 · Primary completion Jan 31, 2022
Drug: SH-1028 tablets; Placebo SH-1028 tablets and 2 more · For: Non-Small Cell Lung Cancer
Nanjing Sanhome Pharmaceutical, Co., Ltd.Industry
NCT03603262 · 85 participants (planned) · Start Apr 25, 2018 · Primary completion Dec 2019
Drug: SH-1028 · For: Non-small Cell Lung Cancer
Sites: Nanjing, China
Nanjing Sanhome Pharmaceutical, Co., Ltd.Industry
NCT04808648 · 40 participants (planned) · Start Apr 6, 2021 · Primary completion Jun 10, 2021
Drug: SH-1028; Itraconazole and 1 more · For: Healthy Male Volunteers
Sites: Bengbu, China
- Pharmacokinetic Study of SH-1028 Tablets in Healthy Subjects Under Fasting and Fed ConditionsStatus unknown
Nanjing Sanhome Pharmaceutical, Co., Ltd.Industry
NCT03973632 · 16 participants (planned) · Start Jul 2019 · Primary completion Dec 2019
Drug: SH-1028 Tablets · For: Healthy Volunteer
Nanjing Sanhome Pharmaceutical, Co., Ltd.Industry
NCT03618043 · 14 participants (planned) · Start Sep 13, 2018 · Primary completion Dec 2019
Drug: SH-1028 · For: Advanced Solid Cancer
Sites: Shanghai, China
- The Absorption, Metabolism and Excretion of [14C]SH-1028 in Chinese Healthy Male VolunteersCompleted
Nanjing Sanhome Pharmaceutical, Co., Ltd.Industry
NCT04810533 · 6 participants · Start May 13, 2020 · Primary completion Mar 5, 2021
Drug: [14C] SH-1028 · For: Healthy Male Volunteers
Sites: Nanjing, China
Newest research
PubMed records naming it or its code names, newest first.
- Absorption, distribution, metabolism, and excretion of [14C]SH-1028, a third-generation EGFR-TKI, in rats and humans.
Zhou S, Wu Y, Liu W, et al. · Front Pharmacol 2026
- [China clinical practice guideline for epidermal growth factor receptor tyrosine kinase inhibitors in stage ࡳ non-small cell lung cancer (version 2023)].
· Zhonghua Yi Xue Za Zhi 2023
- Drug-drug interaction potential of SH-1028, a third-generation EGFR-TKI: in vitro and clinical trials.
Li X, Liu Y, Zhu M, et al. · Invest New Drugs 2023
- Safety, efficacy, and pharmacokinetics of SH-1028 in EGFR T790M-positive advanced non-small cell lung cancer patients: A dose-escalation phase 1 study.
He J, Ma P, Zhao D, et al. · Cancer 2023
- Development and validation of an LC-MS/MS method for simultaneous determination of SH-1028, an irreversible third-generation EGFR TKI, and two of its metabolites in human plasma: application in clinical pharmacokinetics.
Zhou S, Sha B, Wang L, et al. · Xenobiotica 2023
- And Still They Come Over Troubled Waters: Can Asia's Third-Generation EGFR Tyrosine Kinase Inhibitors (Furmonertinib, Aumolertinib, Rezivertinib, Limertinib, Befotertinib, SH-1028, and Lazertinib) Affect Global Treatment of EGFR+ NSCLC.
Lau SCM, Ou SI · J Thorac Oncol 2022
Also in development for Non-small Cell Lung Cancer
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.